TPG Capital fine-tunes details for $3b Novotech sale

TPG Capital aims to sell its clinical trials business Novotech by the end of this year, preparing the formal sales documents for distribution later this month.

The private equity firm has set its sights on rival investment firms as probable buyers of the business, which could fetch TPG at least $3 billion, three people familiar with the process told The Australian Financial Review.